VPA-985, a Nonpeptide Orally Active and Selective Vasopressin V2 Receptor Antagonist-Reference-Cited by-同舟云学术

VPA-985, a Nonpeptide Orally Active and Selective Vasopressin V2 Receptor Antagonist

Published:1998 Issue: Volume: Page:439-443
ISSN:0065-2598
Container-title:Advances in Experimental Medicine and Biology
language:
Short-container-title:

Author:

Chan Peter S.,Coupet Joseph,Park Hyung C.,Lai Fong,Hartupee Dale,Cervoni Peter,Dusza John P.,Albright Jay D.,Ru Xun,Mazandarani Hossein,Tanikella Tarak,Shepherd Cherrie,Ochalski Laura,Bailey Trina,Lock Tim Yeung Wai,Ning Xiaoping,Taylor Joseph R.,Spinelli Walter

Publisher

Springer US

Link

http://link.springer.com/content/pdf/10.1007/978-1-4615-4871-3_55.pdf

Reference14 articles.

1. Beyer KH 1958 The mechanism of action of chlorothiazide. Ann N Y Acad Sci 71:363–379

2. Cervoni P, and Chan PS 1993 Diuretic Agents, In Kirk-Othmer: Encyclopedia of Chemical Technology, 4th Ed., Wiley, Volume 8, pp. 398–432

3. Burnier M, and Brunner HR 1992 Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 13 (Suppl G):28–33

4. Sonnenblick M, Friedlander Y, Rosin AJ 1993 Diuretic-induced severe hyponatremia. Chest 103:601–606

5. Wilcox CS 1996 Diuretics. In Brenner & Rector’s The Kidney. 5th Ed Brenner BM Ed WB Saunders Philadelphia pp 2299–2330

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vasopressin receptor antagonists: a patent summary (2018-2022);Expert Opinion on Therapeutic Patents;2023-05-04

2. Hyponatremia: an update on current pharmacotherapy;Expert Opinion on Pharmacotherapy;2013-03-15

3. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia;Kidney International;2012-12

4. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study;European Journal of Heart Failure;2012-06

5. Assessment of Exposure of Metabolites in Preclinical Species and Humans at Steady State from the Single-Dose Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies: A Case Study;Drug Metabolism and Disposition;2012-04-03